tbuckley/cabot-search huggingface dataset:
Healing transgender women of color in Los Angeles: A transgender-centric delivery of <i>Seeking Safety</i>
Authors: Lois M. Takahashi, Karin Tobin, Fang-Ying Li, Abigail Proff, Jury Candelario
Journal: International Journal of Transgender Health (2020)

Background: Transgender women of Color experience disproportionate rates of HIV, depression, and anxiety, and high rates of substance use, attempted suicide, and interpersonal verbal, physical, and sexual violence and assault. However, there are few interventions targeting transgender women of Color that address overlapping health and mental health challenges.Aims: There are two aims/research questions: (1) what are the elements of a transgender-centric model for delivering evidence based interventions and practices?, and (2) does Seeking Safety improve substance use and mental health outcomes for transgender women of Color?Methods: We present a case study of the delivery process of Seeking Safety by Special Service for Groups/Asian Pacific AIDS Intervention Team (SSG/APAIT), and analyze baseline and three month post program participant data (n = 81).Results: The transgender-centric model of intervention delivery consisted of multiple steps, also integrating the structural disadvantages experienced by transgender women of Color. Comparing baseline and three months after completion showed significant decrease in reported alcohol use, depression, and severe anxiety.Discussion: Transgender-centric approaches may lead to programs that significantly improve co-occurring substance use and mental health for transgender women of Color. We recommend that organizations aiming to existing programs include feedback from members of the communities that the adapted programs aim to help, and in addition, train community members to deliver the programs. The statistical results indicate that Seeking Safety, a trauma-based program with a short program delivery timeline, may show longer term effects on substance use and mental health. We recommend that programs targeting substance use and mental health for transgender women of Color should be combined with services that address disadvantage (i.e., lack of access to housing, income/employment, health care).
1645P Real-world data on cabozantinib in advanced osteosarcoma and Ewing sarcoma - A study of the Hellenic Group of Sarcoma and Rare Cancers
Authors: S. Kokkali-Zervos, A. Ardavanis, M. Panousieris, J. Duran, I. Boukovinas
Journal: Annals of Oncology (2020)
424P Could total neoadjuvant therapy (TNT) become a new standard in locally advanced rectal cancer (LARC)? A systematic review and meta-analysis (MA) of TNT vs. standard chemoradiotherapy (CRT)
Authors: M.C. Riesco Martínez, C. Grávalos, P. Espinosa-Olarte, A. La Salvia, A. Modrego-Sánchez, L. Robles, R. Garcia-Carbonero
Journal: Annals of Oncology (2020)
225P Phase II study of pyrotinib plus albumin-bound paclitaxel and trastuzumab as neoadjuvant treatment in HER2-positive early or locally advanced breast cancer
Authors: T. Luo, X. Zhong, P. He, X. Yan, T. Tian, B. Wei, Z. Zhang, J. Li, H. Zheng
Journal: Annals of Oncology (2020)
Advancing application of mesenchymal stem cell-based bone tissue regeneration
Authors: Fengqing Shang, Yang Yu, Shiyu Liu, Leiguo Ming, Yongjie Zhang, Zhifei Zhou, Jiayu Zhao, Yan Jin
Journal: Bioactive Materials (2020)

Reconstruction of bone defects, especially the critical-sized defects, with mechanical integrity to the skeleton is important for a patient's rehabilitation, however, it still remains challenge. Utilizing biomaterials of human origin bone tissue for therapeutic purposes has provided a facilitated approach that closely mimics the critical aspects of natural bone tissue with regard to its properties. However, not only efficacious and safe but also cost-effective and convenient are important for regenerative biomaterials to achieve clinical translation and commercial success. Advances in our understanding of regenerative biomaterials and their roles in new bone formation potentially opened a new frontier in the fast-growing field of regenerative medicine. Taking inspiration from the role and multicomponent construction of native extracellular matrix (ECM) for cell accommodation, the ECM-mimicking biomaterials and the naturally decellularized ECM scaffolds were used to create new tissues for bone restoration. On the other hand, with the going deep in understanding of mesenchymal stem cells (MSCs), they have shown great promise to jumpstart and facilitate bone healing even in diseased microenvironments with pharmacology-based endogenous MSCs rescue/mobilization, systemic/local infusion of MSCs for cytotherapy, biomaterials-based approaches, cell-sheets/-aggregates technology and usage of subcellular vesicles of MSCs to achieve scaffolds-free or cell-free delivery system, all of them have been shown can improve MSCs-mediated regeneration in preclinical studies and several clinical trials. Here, following an overview discussed autogenous/allogenic and ECM-based bone biomaterials for reconstructive surgery and applications of MSCs-mediated bone healing and tissue engineering to further offer principles and effective strategies to optimize MSCs-based bone regeneration.
1916P Larotrectinib treatment of advanced TRK fusion thyroid cancer
Authors: M.E. Cabanillas, A. Drilon, A.F. Farago, M.S. Brose, R. McDermott, D. Sohal, D-Y. Oh, M. Almubarak, J. Bauman, E. Chu, S. Kummar, S. Leyvraz, K. Park, J.A. Reeves, L. Dima, P. Maeda, L. Rodrigues, N. Brega, D.S. Hong, S.G. Waguespack
Journal: Annals of Oncology (2020)
622P Exploring the impact of treatment switching on the interim overall survival (OS) results of the PROfound study
Authors: N. Agarwal, R. Evans, K. Abrams, P. Dequen-O'Byrne, C. McCrea, D. Muston, C. Gresty, S. Ghate, L. Fan, R. Hettle, N. Hawkins
Journal: Annals of Oncology (2020)
775P Whole blood transcriptomic profiling to predict response to immunotherapy in metastatic urothelial cancer
Authors: S. Van Wilpe, L. Ciarloni, S. Hosseinian Ehrensberger, V. Wosika, J. Schalken, R. Jeitziner, P. Angelino, N. Mehra
Journal: Annals of Oncology (2020)
1036P Patients’ sex and PD-L1 expression jointly associated with overall survival benefits of immune checkpoint inhibitors in cancer
Authors: Y. Yu, A. Li, Y. Chen, W. Zhang, H. Zhong, Y. Gu, Q. Ou, J. Xia, D. Lin, T. Fu, L. Li, R. Liu, H. Yao
Journal: Annals of Oncology (2020)
LBA47 Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs)
Authors: A.J. Stratigos, A. Sekulic, K. Peris, O. Bechter, C. Dutriaux, M. Kaatz, K.D. Lewis, N. Basset-Seguin, A.L.S. Chang, S. Dalle, A. Fernandez-Orland, L. Licitra, C. Robert, C. Ulrich, A. Hauschild, M.R. Migden, R. Dummer, S. Li, T. Bowler, M.G. Fury
Journal: Annals of Oncology (2020)
1791P Effect of anlotinib in advanced small cell lung cancer (SCLC) patients with liver metastases: A subgroup analysis from a randomized, double-blind phase II trial (ALTER 1202)
Authors: Y. Cheng, Q. Wang, K. Li, J. Shi, L. Wu, B. Han, G. Chen, J. He, J. Wang, H. QIN, X. Li
Journal: Annals of Oncology (2020)
Asthma and all-cause mortality in children and young adults: a population-based study
Authors: Emma Caffrey Osvald, Hannah Bower, Cecilia Lundholm, Henrik Larsson, Bronwyn K Brew, Catarina Almqvist
Journal: Thorax (2020)

Background Studies suggest an increased all-cause mortality among adults with asthma. We aimed to study the relationship between asthma in children and young adults and all-cause mortality, and investigate differences in mortality rate by also having a life-limiting condition (LLC) or by parental socioeconomic status (SES). Methods Included in this register-based study are 2 775 430 individuals born in Sweden between January 1986 and December 2012. We identified asthma cases using the National Patient Register (NPR) and the Prescribed Drug Register. Those with LLC were identified using the NPR. Parental SES at birth (income and education) was retrieved from Statistics Sweden. We estimated the association between asthma and all-cause mortality using a Cox proportional hazards regression model. Effect modification by LLC or parental SES was studied using interaction terms in the adjusted model. Results The adjusted hazard rate (adjHR) for all-cause mortality in asthma cases versus non-asthma cases was 1.46 (95% CI 1.33 to 1.62). The highest increased rate appeared to be for those aged 5–15 years. In persons with asthma and without LLC, the adjHR remained increased at 1.33 (95% CI 1.18 to 1.50), but differed (p=0.002) from those with asthma and LLC, with an adjHR of 1.87 (95% CI 1.57 to 2.22). Parental SES did not alter the association (income, p=0.55; education, p=0.83). Conclusion This study shows that asthma is associated with an increased mortality in children and young adults regardless of LLC or parental SES. Further research is warranted to investigate the possible mechanisms for this association.
1047P Long terms efficacy of anti-PD(L)1 in MSI tumours
Authors: C. Smolenschi, P. Vuagnat, Y. el Dakdouki, E.R. Elie, B. Cheaib, N-B. Laetitia, C. Massard, P. Martin Romano, M.P. Ducreux, V. Boige, D. Malka, A. Perret, A.C. Fuerea, B. Pascal, C. Prieux, A. Hollebecque
Journal: Annals of Oncology (2020)
Raising the threshold for hospital admission and endoscopy in upper gastrointestinal bleeding during the COVID-19 pandemic
Authors: Stig B. Laursen, Ian M. Gralnek, Adrian J. Stanley
Journal: Endoscopy (2020)

See also: Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) GuidelineEndoscopy 2015; 47(10): a1-a46DOI: 10.1055/s-0034-1393172
189P The prognostic value of androgen receptor in triple negative breast cancer
Authors: D. Pratiwi, I. Purwanto, M.S. Hardianti, J. Kurnianda, K. Widayati, S.H. Hutajulu, T. Aryandono, S. Mubarika, A. Ghozali, I. Irianiwati
Journal: Annals of Oncology (2020)
635P ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levels
Authors: A. Alcaraz, R.Z. Szmulewitz, N. Shore, E.D. Crawford, D.P. Petrylak, J. Holzbeierlein, A. Villers, A.A. Azad, B. Alekseev, T. Iguchi, F. Gomez-Veiga, B. Rosbrook, J. Sugg, G.P. Haas, A. Stenzl, A.J. Armstrong
Journal: Annals of Oncology (2020)
61P Gender and race/ethnicity differences in outcomes of biliary cancers (BC): A SEER database analysis
Authors: H.J. Lenz, C. Luo, P. Jayachandran, H. Arai, J. Wang, N. Kawanishi, S. Soni, A.B. El-Khoueiry, W. Zhang, J. Millstein, F. Battaglin
Journal: Annals of Oncology (2020)
1084P Cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma (mCSCC): Preliminary safety and efficacy results from a phase I clinical trial
Authors: P. Clingan, D. Brungs, R. Ladwa, A.M. Mant, M. McGrath, A. Tazbirkova, P. Koralewski, I. Lugowska, C. Charoentum, A. Dechaphunkul, V. Sriuranpong, J. Oliviero, D.L. Harris
Journal: Annals of Oncology (2020)
223P Safety and tolerability of subcutaneous trastuzumab (H SC) self-administered at home via single-use injection device (SID) in patients (pts) with HER2-positive early breast cancer (EBC): Primary and final analysis of the open-label, phase IIIB HOMERUS study
Authors: A.J. ten Tije, S. van Steenis, J. Briers, E.M.P. Elsten
Journal: Annals of Oncology (2020)
1020O A phase I, first-in-human, open-label, dose escalation study of MGD019, an investigational bispecific PD-1 x CTLA-4 DART® molecule in patients with advanced solid tumours
Authors: M. Sharma, R.E. Sanborn, G.M. Cote, J.C. Bendell, S. Kaul, F. Chen, A. Berezhnoy, P. Moore, E. Bonvini, B.J. Sumrow, J.J. Luke
Journal: Annals of Oncology (2020)
963P Clinical and histological prognostic factors of recurrent and/or metastatic salivary gland adenoid cystic carcinoma
Authors: L. Lorini, C. Gurizzan, M. Tomasoni, D. Lombardi, D. Mattavelli, A. Paderno, A. Deganello, L. Ardighieri, S. Battocchio, A. Bozzola, M. Ravanelli, M. Maddalo, M. Zamparini, S.M. Magrini, R. Maroldi, P. Nicolai, A. Berruti, P. Bossi
Journal: Annals of Oncology (2020)
957P Ameloblastoma of the head and neck (HNAMB): A comprehensive profiling (CGP) study
Authors: P. Reddy, N.A. Danziger, J. Elvin, J-A. Vergilio, J.K. Killian, D.I. Lin, E. Williams, S. Ramkissoon, E. Severson, A. Hemmerich, D. Duncan, C. Edgerly, R. Huang, M. Hiemenz, J.H. Chung, K. McGregor, J. Venstrom, A.B. Schrock, B. Alexander, J.S. Ross
Journal: Annals of Oncology (2020)
The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics
Authors: Trent M. Woodruff, Arun K. Shukla
Journal: Trends in Immunology (2020)

The current pandemic of coronavirus disease (COVID-19) caused by SARS-CoV-2 is a significant global health challenge. A recent study by Carvelli and colleagues now demonstrates the involvement of complement C5a and its receptor C5aR1 in disease progression and suggests that blockade of the C5a-C5aR1 axis may represent a potential therapeutic strategy against COVID-19.
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort
Authors: Laurence Albiges, Stéphanie Foulon, Arnaud Bayle, Bertrand Gachot, Fanny Pommeret, Christophe Willekens, Annabelle Stoclin, Mansouria Merad, Frank Griscelli, Ludovic Lacroix, Florence Netzer, Thomas Hueso, Corinne Balleyguier, Samy Ammari, Emeline Colomba, Giulia Baciarello, Audrey Perret, Antoine Hollebecque, Julien Hadoux, Jean-Marie Michot, Nathalie Chaput, Veronique Saada, Mathilde Hauchecorne, Jean-Baptiste Micol, Roger Sun, Dominique Valteau-Couanet, Fabrice André, Florian Scotte, Benjamin Besse, Jean-Charles Soria, Fabrice Barlesi
Journal: Nature Cancer (2020)

Patients with cancer are presumed to be at increased risk of severe COVID-19 outcomes due to underlying malignancy and treatment-induced immunosuppression. Of the first 178 patients managed for COVID-19 at the Gustave Roussy Cancer Centre, 125 (70.2%) were hospitalized, 47 (26.4%) developed clinical worsening and 31 (17.4%) died. An age of over 70 years, smoking status, metastatic disease, cytotoxic chemotherapy and an Eastern Cooperative Oncology Group score of ≥2 at the last visit were the strongest determinants of increased risk of death. In multivariable analysis, the Eastern Cooperative Oncology Group score remained the only predictor of death. In contrast, immunotherapy, hormone therapy and targeted therapy did not increase clinical worsening or death risk. Biomarker studies found that C-reactive protein and lactate dehydrogenase levels were significantly associated with an increased risk of clinical worsening, while C-reactive protein and D-dimer levels were associated with an increased risk of death. COVID-19 management impacted the oncological treatment strategy, inducing a median 20 d delay in 41% of patients and adaptation of the therapeutic strategy in 30% of patients.
570P A first-in-human phase I study of the AXL inhibitor DS-1205c in combination with gefitinib in subjects with EGFR-mutant NSCLC
Authors: M. Nishio, I. Okamoto, H. Murakami, H. Horinouchi, R. Toyozawa, M. Takeda, M. Uno, N. Crawford, T. Jimbo, M. Ishigami, G. Takayama, S. Nakayama, S. Ohwada, E. Slosberg, K. Goto
Journal: Annals of Oncology (2020)
937P Outcome, patterns of failure and toxicity profile following adjuvant intensity modulated radiotherapy for oral cavity squamous cell carcinomas
Authors: T. Basu, A. Karpe, Y. Mathur, A. Patel, P. Kendre, R. Katna, N. Raut, D. Rodrigues, R. Yadav, D. Nayak, I. Ambulkar, S. Gawde
Journal: Annals of Oncology (2020)
Recurrence of Immune-Related Adverse Events After Immune Checkpoint Inhibitor Rechallenge—Reply
Authors: Charles Dolladille, Angélique Da-Silva, Joachim Alexandre
Journal: JAMA Oncology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
471P Identification and validation of a new prognostic score in metastatic colorectal cancer (mCRC): GEMCAD score
Authors: E. Seguí, V. Alonso-Orduna, A. Sesma, M. Martin-Richard, A. Salud, A. Fernández-Montes, C. Fernández-Martos, A. Ruiz-Casado, J. Gallego, J. Aparicio, E. Gálvez, H. Manzano, J. Alcaide-Garcia, R. Gallego, E. Falco, F. Esposito, H. Oliveres, F. Torres, J. Feliu, J. Maurel
Journal: Annals of Oncology (2020)
1031P Tilsotolimod engages the TLR9 pathway to promote antigen presentation and type I IFN signaling in solid tumours
Authors: H. Babiker, E. Borazanci, V. Subbiah, A.P. Algazi, J. Schachter, M. Lotem, D. Hendler, S. Rahimian, H. Minderman, C. Haymaker, C. Bernatchez, R. Murthy, R. Hultsch, N. Caplan, G.J. Woodhead, C.T. Hennemeyer, S. Chunduru, P. Anderson, A. Diab, I. Puzanov
Journal: Annals of Oncology (2020)
1458P Real-world treatment patterns of unresectable advanced or synchronous metastatic esophageal squamous cell cancer in a Western population
Authors: M. Pape, P.A.J. Vissers, J. de vos-Geelen, M.C.C.M. Hulshof, H.W.M. van Laarhoven, R.H. Verhoeven
Journal: Annals of Oncology (2020)
982P Comparison of donafenib and sorafenib as advanced hepatocellular carcinoma first-line treatments: Subgroup analysis of an open-label, randomized, parallel-controlled, multicentre phase II/III trial
Authors: S. Qin, F. Bi, C. Cui, B. Zhu, J. Wu, X. Xin, J. Wang, J. Shan, J. Chen, Z. Zheng, L. Xu, X. Wen, Z. You, Z. Ren, X. Wu
Journal: Annals of Oncology (2020)
LBA5_PR Abemaciclib in high risk early breast cancer
Authors: S.R.D. Johnston, N. Harbeck, R. Hegg, M. Toi, M. Martin, Z. Shao, M. Campone, E.P. Hamilton, J. Sohn, V. Guarneri, J. Cortés, P. Neven, F. Boyle, I. Smith, D. Headley, R. Wei, M. Frenzel, J. Cox, J. O'Shaughnessy, P. Rastogi
Journal: Annals of Oncology (2020)
LBA2 Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study
Authors: B. Solomon, T.M. Bauer, F. De Marinis, E. Felip, Y. Goto, G. Liu, J. Mazieres, D-W. Kim, T. Mok, A. Polli, H. Thurm, A.M. Calella, G. Peltz, A. Shaw
Journal: Annals of Oncology (2020)
CN2 The roadmap of oncology nursing specialisation in Spain
Authors: N. Gil Gómez, R. Cumplido Corbacho, N. Domenech-Climent, J.C. de la Torre-Montero, P. Beorlegui Murillo, J.M. Gavala Arjona, I. Magallon Pedrera, M.Á. Peñuelas Saiz
Journal: Annals of Oncology (2020)
903P Combination of nivolumab with brentuximab vedotin in therapy of relapsed and refractory Hodgkin lymphoma
Authors: L. Fedorova, K. Lepik, N. Mikhailova, E. Kondakova, P. Kotselyabina, D.I. Shmidt, A. Kozlov, Y. Zalyalov, E. Borzenkova, V. Baykov, I. Moiseev, A. Kulagin
Journal: Annals of Oncology (2020)
1573P Anxiety and depression in cancer patients during the COVID-19 pandemic: A single-centre study
Authors: F. Letaief-Ksontini, Y. Zenzri, Y. Yahyaoui, A. Gabsi, A. Mokrani, K. Meddeb, None F. mghirbi, H. Rais, M. Ayadi, N. Chraiet, A. Mezlini
Journal: Annals of Oncology (2020)
Spatiotemporal restriction of endothelial cell calcium signaling is required during leukocyte transmigration
Authors: Prarthana J. Dalal, David P. Sullivan, Evan W. Weber, David B. Sacks, Matthias Gunzer, Isabella M. Grumbach, Joan Heller Brown, William A. Muller
Journal: The Journal of Experimental Medicine (2020)

Endothelial cell calcium flux is critical for leukocyte transendothelial migration (TEM), which in turn is essential for the inflammatory response. Intravital microscopy of endothelial cell calcium dynamics reveals that calcium increases locally and transiently around the transmigration pore during TEM. Endothelial calmodulin (CaM), a key calcium signaling protein, interacts with the IQ domain of IQGAP1, which is localized to endothelial junctions and is required for TEM. In the presence of calcium, CaM binds endothelial calcium/calmodulin kinase IIδ (CaMKIIδ). Disrupting the function of CaM or CaMKII with small-molecule inhibitors, expression of a CaMKII inhibitory peptide, or expression of dominant negative CaMKIIδ significantly reduces TEM by interfering with the delivery of the lateral border recycling compartment (LBRC) to the site of TEM. Endothelial CaMKII is also required for TEM in vivo as shown in two independent mouse models. These findings highlight novel roles for endothelial CaM and CaMKIIδ in transducing the spatiotemporally restricted calcium signaling required for TEM.
843P Association of gene expression signatures and TMB with response to pembrolizumab (pembro) in patients (pts) with recurrent ovarian cancer (ROC) enrolled in KEYNOTE-100
Authors: J.A. Ledermann, R. Shapira-Frommer, A.D. Santin, A. Lisyanskaya, S. Pignata, I.B. Vergote, F. Raspagliesi, G.S. Sonke, M. Birrer, D. Provencher, J. Sehouli, N. Colombo, A. González Martín, A. Oaknin, A. Saadatpour, J. Kobie, P. Jelinic, K. Stein, U.A. Matulonis
Journal: Annals of Oncology (2020)
943P The most optimal induction chemotherapy regimen for loco-regionally advanced nasopharyngeal carcinoma: A network meta-analysis
Authors: S.K. Chan, C.W. Choi, K.O. Lam, S.Y. Chan, S.C. Chau, D.L.W. Kwong, T.W. Leung, M.Y. Luk, A.W.M. Lee, V.H.F. Lee
Journal: Annals of Oncology (2020)
2008P The effect of the use of complex molecular profiling in advanced solid organ tumours on clinical decision: Turkey molecular profiling in advanced cancers trial (TUMPACT)
Authors: O.F. Olmez, A. Bilici, Ö. Er, A. Sevinç, T. Akman, R. Uslu, N.M. Mandel, Ş. Yalçın, M. Teomete, G. Görümlü, A. Demir, E. Namal, S. Alıcı, F. Selçukbiricik, S. Bavbek, F. Paksoy, G. Başaran, L. Özer, N. Şener, H. Harputluoğlu
Journal: Annals of Oncology (2020)
954P Changes in levels of cytokines and interleukins during nivolumab treatment: A subgroup analysis of the NIVACTOR study
Authors: M. Paccagnella, N. Denaro, A. Falletta, A. Abbona, D. Galizia, L. De Zarlo, E. Fiorino, L. Gammaitoni, D. Sangiolo, M.C. Merlano
Journal: Annals of Oncology (2020)
756P Molecular subtyping and immune-gene signatures identify a subset of clinical T1 high-grade (cT1 HG) and cT2 bladder urothelial carcinoma (UC) as candidates for single-agent immune checkpoint inhibition (ICI)
Authors: A. Necchi, D. Raggi, A. Gallina, M. Bandini, P. Giannatempo, L. Marandino, M. Colecchia, A. Briganti, F. Montorsi, E. Davicioni, Y. Lotan, E. Gibb
Journal: Annals of Oncology (2020)
Plymouth trust is first to be fined for breaching duty of candour rules
Authors: Clare Dyer
Journal: BMJ (2020)

An NHS hospital trust has been ordered to pay a total of £12 565 (€13 732; $16 005) after admitting failing to explain to a 91 year old woman’s family how an endoscopy went wrong and she died after a perforated oesophagus, in the first prosecution to be brought for breaching the duty of candour.

University Hospitals Plymouth NHS Trust was fined £1600 and ordered to pay £10 845.43 costs and a £120 victim surcharge at Plymouth magistrates court, after a prosecution by the Care Quality Commission (CQC). The maximum fine that can be imposed is £2500 and the trust was given credit for pleading guilty early.

The CQC brought the prosecution after discovering that the trust failed to tell Elsie Woodfield’s family …